Lixisenatide: difference between revisions
Diff·revision 8 → 9·21:52, 10 Feb 2025
Difference between revision 8 and revision 9 of Lixisenatide. 6 lines changed; the page grew by 99 bytes.
| Revision 8 — 20:31, 23 Jan 2025 StyleSheetSybil (talk) rm duplicated pharmacokinetics — the same figures appear in the infobox 2,936 bytes +634 | Revision 9 — 21:52, 10 Feb 2025 CuriousCallum (talk) state the substitution in one-letter code as well, per PP:MOS 3,035 bytes +99 | ||
|---|---|---|---|
| 31 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> | 31 | <ref name="drucker2018">Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." ''Cell Metabolism'' 27(4):740–756 (2018). PMID 29617641.</ref> |
| 32 | 32 | ||
| + | 33 | == See also == | |
| + | 34 | * [[Exenatide]] | |
| + | 35 | * [[GLP-1 receptor agonist]] | |
| + | 36 | * [[LEADER trial]] | |
| + | 37 | * [[SELECT trial]] | |
| + | 38 | ||
| 33 | {{DEFAULTSORT:Lixisenatide}} | 39 | {{DEFAULTSORT:Lixisenatide}} |
| 34 | [[Category:GLP-1 receptor agonists]] | 40 | [[Category:GLP-1 receptor agonists]] |